NDAORAL SUSPENSIONTABLETPriority Review
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
Priority Review
DOLUTEGRAVIR SODIUM (dolutegravir sodium) by Viatris is fixed-dose combination of the hiv‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see microbiology ()].
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Dolutegravir sodium is a fixed-dose combination HIV-1 antiretroviral containing abacavir, dolutegravir, and lamivudine in oral tablet and suspension formulations. It works through integrase strand transfer inhibition combined with nucleoside reverse transcriptase inhibitors to suppress HIV replication. This combination targets HIV-1 infected patients requiring multi-agent antiretroviral therapy.
PRE_LAUNCH
As a pre-launch product, positions team members in high-impact launch operations, commercialization strategy, and market entry planning with Viatris' HIV franchise.
Mechanism of Action
fixed-dose combination of the HIV‑1 antiretroviral agents abacavir, dolutegravir, and lamivudine [see Microbiology ()].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch asset offers high visibility into HIV market dynamics, formulary access negotiations, and Viatris' antiretroviral strategy. Team members will drive launch execution, physician education, and payer relationships in a therapeutic area with significant unmet adherence needs.
Brand ManagerField Sales Representative
Worked on DOLUTEGRAVIR SODIUM at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.